Please login to the form below

Not currently logged in
Email:
Password:

tisagenleucel

This page shows the latest tisagenleucel news and features for those working in and with pharma, biotech and healthcare.

Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

tisagenleucel). Axovant CEO Pavan Cheruvu, who took the helm of the company after David Hung and other senior execs resigned in the wake of the intepirdine failure, said the company will

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...

Infographics